AwesomeCapital
Search This Blog
Friday, March 31, 2023
Bellerophon Clinical Program Update and Full-Year 2022 Financial Results
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023
Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China
https://www.biospace.com/article/releases/bellerophon-provides-clinical-program-update-and-reports-full-year-2022-financial-results/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.